BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 9891519)

  • 1. Relationships between different measurements of vascularity and clinico-pathological parameters in breast cancer.
    Pendleton N; Pazouki S; Heerkens E; Smither RL; Chisholm DM; Moore JV; Howell A; Horan MA; Schor AM
    Anticancer Res; 1998; 18(6B):4565-8. PubMed ID: 9891519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Flt-4-positive vessel density correlates with vascular endothelial growth factor-d expression, nodal status, and prognosis in breast cancer.
    Nakamura Y; Yasuoka H; Tsujimoto M; Yang Q; Imabun S; Nakahara M; Nakao K; Nakamura M; Mori I; Kakudo K
    Clin Cancer Res; 2003 Nov; 9(14):5313-7. PubMed ID: 14614015
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multivariate analysis of bcl-2, apoptosis, P53 and HER-2/neu in breast cancer: a short-term follow-up.
    el-Ahmady O; el-Salahy E; Mahmoud M; Wahab MA; Eissa S; Khalifa A
    Anticancer Res; 2002; 22(4):2493-9. PubMed ID: 12174951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 17 beta-Hydroxysteroid dehydrogenase type 1 and type 2 in ductal carcinoma in situ and intraductal proliferative lesions of the human breast.
    Ariga N; Moriya T; Suzuki T; Kimura M; Ohuchi N; Satomi S; Sasano H
    Anticancer Res; 2000; 20(2B):1101-8. PubMed ID: 10810403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
    Badve S; Turbin D; Thorat MA; Morimiya A; Nielsen TO; Perou CM; Dunn S; Huntsman DG; Nakshatri H
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4415-21. PubMed ID: 17671124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of vascular endothelial growth factor D in breast carcinoma with long-term follow-up.
    Nakamura Y; Yasuoka H; Tsujimoto M; Yang Q; Imabun S; Nakahara M; Nakao K; Nakamura M; Mori I; Kakudo K
    Clin Cancer Res; 2003 Feb; 9(2):716-21. PubMed ID: 12576440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunohistochemical localization of metallothionein in human breast cancer in comparison with cathepsin D, stromelysin-1, CD44, extracellular matrix components, P53, Rb, C-erbB-2, EGFR, steroid receptor content and proliferation.
    Ioachim E; Kamina S; Demou A; Kontostolis M; Lolis D; Agnantis NJ
    Anticancer Res; 1999; 19(3A):2133-9. PubMed ID: 10470161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation of clinical, pathological status, hormone receptor and C-erbB-2 oncoprotein in breast cancer patients.
    Aryandono T; Harijadi ; Ghozali A
    Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():600-6. PubMed ID: 10895217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Combined surgery and radiotherapy in the treatment of ductal carcinoma in situ of the breast: preliminary results of the Hungarian multicenter prospective randomised study].
    Polgár C; Orosz Z; Kahán Z; Gábor G; Jani N; Cserni G; Hadijev J; Kulka J; Sulyok Z; Boross G; Lázár G; László Z; Diczházi C; Udvarhelyi N; Szabó E; Péntek Z; Major T; Fodor J
    Magy Onkol; 2008 Sep; 52(3):269-77. PubMed ID: 18845497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study.
    Ottesen GL
    APMIS Suppl; 2003; (108):1-67. PubMed ID: 12874968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiogenesis as determined by computerised image analysis and the risk of early relapse in women with invasive ductal breast carcinoma.
    Olewniczak S; Chosia M; Kołodziej B; Kwas A; Kram A; Domagała W
    Pol J Pathol; 2003; 54(1):53-9. PubMed ID: 12817881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of GCDFP-15 and AR decreases in larger or node-positive apocrine carcinomas of the breast.
    Honma N; Takubo K; Akiyama F; Sawabe M; Arai T; Younes M; Kasumi F; Sakamoto G
    Histopathology; 2005 Aug; 47(2):195-201. PubMed ID: 16045781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunohistochemical detection of p53 protein expression in breast cancer in young Kuwaiti women.
    Temmim L; Baker H; Sinowatz F
    Anticancer Res; 2001; 21(1B):743-8. PubMed ID: 11299837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Significance of periductal lymphatic and blood vascular densities in intraductal carcinoma of the breast.
    El-Gohary YM; Metwally G; Saad RS; Robinson MJ; Mesko T; Poppiti RJ
    Breast J; 2009; 15(3):261-7. PubMed ID: 19645781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
    Hussein MR; Abd-Elwahed SR; Abdulwahed AR
    Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nitric oxide in breast cancer: induction of vascular endothelial growth factor-C and correlation with metastasis and poor prognosis.
    Nakamura Y; Yasuoka H; Tsujimoto M; Yoshidome K; Nakahara M; Nakao K; Nakamura M; Kakudo K
    Clin Cancer Res; 2006 Feb; 12(4):1201-7. PubMed ID: 16489074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Immunohistochemical research on breast cancer cell proliferation and hormonal receptor status with special emphasis on HER-2/neu expression].
    Ohlinger R; Steffen SM; Oellig F; Köhler G; Schwesinger G; Lorenz G
    Zentralbl Gynakol; 2002 Oct; 124(10):473-7. PubMed ID: 12712389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer.
    Saha B; Zhang N; Naritoku WY; Tsao-Wei DD; Groshen SL; Carlsson G; Larsson L; Gustavsson B; Chaiwun B; Taylor CR; Imam SA
    Anticancer Res; 2004; 24(4):2391-400. PubMed ID: 15330189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The presence of serum anti-p53 antibodies from patients with invasive ductal carcinoma of breast: correlation to other clinical and biological parameters.
    Gao RJ; Bao HZ; Yang Q; Cong Q; Song JN; Wang L
    Breast Cancer Res Treat; 2005 Sep; 93(2):111-5. PubMed ID: 16187230
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.